解放军医药杂志Issue(1)：48-51,4.DOI:10.3969/j.issn.2095-140X.2015.01.009
DC-CIK治疗对辅助化疗后三阴乳腺癌的临床疗效观察
Clinical Effect of DC-CIK in Treatment of Three Negative Breast Cancer after Adjuvant Chemotherapy
摘要
Abstract
Objective To explore clinical effect of autologous DC-CIK ( dendritic cell-cytokine-induced killer) cells immunotherapy on three negative breast cancer after adjuvant chemotherapy. Methods Clinical data of 65 postop-erative patients with three negative breast cancer during January 2003 and November 2012 after surgery were collected. After postoperative corresponding cycles of chemotherapy for 1-2 months, 37 patients ( observation group) underwent au-tologous DC-CIK cells immunotherapy cultured in vitro. The 28 patients ( control group) received regular follow-up. The changes of tumor markers, immunity indexes, the targeting drug-related adverse reactions, quality of life and overall sur-vival rate before and after DC-CIK cells immunotherapy were observed. Results The differences in tumor markers ( CEA and CA15-3 ), immunity indexes (CD3, CD4 and CD8) before and after adjuvant chemotherapy in observation group showed no statistical significances ( P>0. 05 ); while the differences in targeting drug-related toxic reactions ( fatigued and weak, nausea and vomiting, emotional depression and sleeplessness) in the two groups showed statistical signifi-cances (P<0. 05). Conclusion DC-CIK cell immunotherapy for three negative breast cancer after adjuvant chemother-apy provides a new therapeutic method, and may relieve targeting drug-related toxic reactions, improve quality of life and prolong overall survival time.关键词
细胞因子诱导杀伤细胞/乳腺肿瘤/化学疗法,辅助Key words
Cytokine-induced killer cells/Breast neoplasms/Chemotherapy, adjuvant分类
医药卫生引用本文复制引用
朱欢欢,马东初,丁震宇,韩涛,郭放,刘兆喆,韩雅玲,谢晓冬..DC-CIK治疗对辅助化疗后三阴乳腺癌的临床疗效观察[J].解放军医药杂志,2015,(1):48-51,4.基金项目
科技部十二五重大新药创制平台子课题(2012ZX09303016-002) （2012ZX09303016-002）
2012年辽宁省科技攻关计划课题(2012225019) （2012225019）
